Ketamine for Depression in Parkinson's Disease (KET-PD Trial)

"Affirmative. The information posted on clinicaltrials.gov confirms that the research is actively seeking participants, with a recruitment window starting November 23 2021 and ending August 22 2022. The study seeks 56 volunteers from 1 medical centre."

"According to the criteria, participants should be between 40 and 75 years old. Conversely, there are 229 trials available for youths below 18 and over 1,500 studies open to seniors above 65."

"Although there is evidence of some safety benefits associated with Ketamine Infusion, the lack of efficacy data preclude a score higher than 2 on our scale."

"This research is recruiting 56 adults aged between 40 and 75 who have depression. To be considered, potential participants must satisfy the following requirements: Male or female age range of 40 to 75 years; Diagnosis of Parkinson's disease according to the Hoehn and Yahr Scale (level 1-3); Evidence of Major Depressive Disorder as established by Mini International Neuropsychiatric Interview (MINI) with a MADRS score above 15; For women capable of reproductive, contraception use for at least four weeks before screening plus agreement to maintain its application during trial period along with negative pregnancy test results; Refrainment from drugs other than alcohol, cannabis"

"According to the data posted on clinicaltrials.gov, this research is still open for participants. It was initially advertised on November 23rd 2021 and had its most recent update August 22nd 2022."